Plasmid-mediated AmpC producing proteus mirabilis in the health care area of santiago de compostela: Molecular and epidemiological analysis by rep-PCR and MALDI-TOF;Proteus mirabilis productor de ampc plasmídica en el área sanitaria de santiago de compostela: Prevalencia y caracterización molecular por rep-PCR y MALDI-TOF MS

Revista Espanola de Quimioterapia

Volumn 25, Issue 2, 2012, Pages 122-128

  Treviño, Mercedes ^a   Navarro, Daniel ^a   Barbeito, Gema ^a   Areses, Paloma ^a   García Riestra, Carlos ^a   Regueiro, Benito J ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

AMPc; Diversilab; MALDI TOF; Proteus

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPC TYPE BETA LACTAMASE; BETA LACTAMASE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; UNCLASSIFIED DRUG;

AMPC TYPE BETA LACTAMASE PRODUCING PROTEUS MIRABILIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GENETIC VARIABILITY; HEALTH CARE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PHENOTYPE; PLASMID; POLYMERASE CHAIN REACTION; PROTEUS MIRABILIS; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CHILE; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; PLASMIDS; POLYMERASE CHAIN REACTION; PROTEUS INFECTIONS; PROTEUS MIRABILIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; URINARY TRACT INFECTIONS;

EID: 84863659336     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Adler H, Fenner L, Walter P, Hohler D, Schultheiss E, Oezcan S, et al. Plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes: prevalence at a Swiss university hospital and occurrence of the different molecular types in Switzerland. J Antimicrob Chemother 2008; 61: 457-458.
2. Bret L, Chanal-Claris C, Sirot D, Chaibi EB, Labia R, Sirot J. Chromosomically encoded AmpC-type beta-lactamase in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother 1998; 42: 1110-1114.
3. Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to expression of extended-spectrum beta-lactamase. Antimicrob Agent Chemother 2005; 49: 2598-2605.
4. Park YJ, Lee S, Kim YR, Oh EJ, Woo EJ, Lee K. Occurrence of extended-spectrum beta-lactamases and plasmid-mediated AmpC beta-lactamases among Korean isolates of Proteus mirabilis. J Antimicrob Chemother 2001; 57: 156-158.
5. Mata C, Miró E, Rivera A, Mirelis B, Coll P, Navarro F. Prevalence of aquired AmpC beta-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes at a Spanish hospital from 1999 to 2007. Clin Microbiol Infect 2010; 16: 472-476.
6. Bidet P, Verdet C, Gautier V, Bingen E, Arlet G. First description of DHA-1 ampC beta-lactamase in Proteus mirabilis. Clin Microb Infect 2005; 11: 591-592
7. Literacka E, Empel J, Baraniak A, Sadowy E, Hrniewicz W, Gniadkowski M. Four variants of the Citrobacter freundii AmpC-type cephalosporinases, including novel enzymes CMY-14 and CMY-15, in a Proteus mirabilis clone widespread in Poland. Antimicrob Agents Chemother 2004; 48: 4136-4143.
8. Aragón ML, Mirelis B, Miró E, Mata C, Gómez L, Rivera A, Coll P, Navarro F. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases. J Antimicrob Chemother 2008; 61: 1029-1032.
9. Pitout JD, Gregson DB, Church DL, Laupland KB. Populationbased laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerg Infect Dis 2007; 13: 443-448.
10. Hopkins KL, Batchelor MJ, Liebana E, Deheer-Graham AP, Threlfal EJ. Characterization of CTX-M and AmpC genes in human isolates of Escherichia coli identified between 1995 and 2003 in England and Wales. Int J Antimicrob Agents 2006; 28: 180-192.
11. Grisold AJ, Zarfel G, Strenger V, Feierl G, Leitner E, Masoud L et al. Use of automated repetitive-sequence-based PCR for rapid laboratory confirmation of nosocomial outbreaks. J Infect 2010; 60: 44-51.
12. Healy M, Huong L, Bittner T, Lising M, Frye S, Raza S et al. Microbial DNA typing by automated repetitive-sequence-based PCR. J Clin Microbiol 2005; 43: 199-207.
13. Siegrist TJ, Anderson PD, Huen WH, Kleinheinz GT, McDermott CM, Sandrin TR. Discrimination and characterization of environmental strains of Escherichia coli by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). J Microbiol Methods 2007; 68: 554-562.
14. Rezzonico F, Vogel G, Duffy B, Tonolla M. Whole Cell MALDITOF Mass Spectrometry application for rapid identification and clustering analysis of Pantoea species. Appl Environ Microbiol 2010; 76: 4497-4509.
15. Clinical Laboratory Standards Institute: Performance Standards for antimicrobial susceptibility testing. Seventeenth informational supplement M100-S20. Clinical and Laboratory Standard Institute, Wayne, PA 2010.
16. Yagi, T, Wachino J, Kurokawa H, Suzuki S, Yamane K, Doi Y et al. Practical methods using boronic acid compounds for identification of Class C-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol 2005; 43: 2551-2558.
17. Ruppe E, Bidet P, Verdet C, Arlet G, Bingen E. First detection of the Ambler Class C1 AmpC-lactamase in Citrobacter freundii by a new, simple double-disk synergy test J Clin Microbiol 2006, 44: 4204-4207.
18. Pérez-Pérez, ND, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002, 40: 2153-2162.
19. Empel J, Baraniak A, Literacka E, Mrówka A, Fiett J, Sadowy E et al. and the Beta-PL Study Group. Molecular survey of betalactamases conferring resistance to neweer beta-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agentes Chemother 2008; 52: 2449-2454.
20. Luzzaro F, Brigante G, Dándrea MM, Pini B, Giani T, Mantegoli E et al. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents 2009; 33: 328-333.
21. Ferrán Navarro Risueño, Elisenda Miró Cardona y Beatriz Mirelis Otero. Lectura interpretada del antibiograma de enterobacterias. Enferm Infecc Microbiol Clin 2002; 20:225-234.
22. Jacoby GA. AmpC beta-lactamases. Clin Microb Rev 2009; 22: 161-182.
23. Tenover, FC, Emery SL, Spiegel CA, Bradford PA, Eells, S Endimiani A et al. Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J Clin Microbiol 2009; 47: 294-299.
24. D'Andrea MM, Nucleo E, Luzzaro F, Giani T, Migliavaca R, Vailati F et al. CMY-16, a novel acquired Ampc-type beta-lactamase of CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy. Antimicrob Agents Chemother 2006; 50: 618-624.